Literature DB >> 7605851

Review article: the hypersensitive gut--peripheral kappa agonists as a new pharmacological approach.

J L Junien1, P Riviere.   

Abstract

Hypersensitivity to pain is a common component of functional bowel disorders. Hyperalgesia may be induced by various stimuli which produce a cocktail of inflammatory mediators that decrease the pain threshold. Drugs able to block these peripheral events within the gut may offer a new pharmacological approach for treating functional bowel disorders. Kappa opioids have been shown to inhibit somatic pain through a peripheral mechanism of action, acting directly on receptors located on peripheral sensory endings. They can block both the nociceptive messages as well as the release of sensory peptides. This paper reviews the effects of opioid agonists on gut visceral pain and motility anomalies induced by visceral pain. Kappa opioids have strong effects on all models tested, with a peripheral mechanism of action allowing the design of drugs acting only in the periphery and having no central nervous system side-effects. This contrasts with mu agonists which are centrally active on pain and worsen the subsequent transit and motility anomalies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7605851     DOI: 10.1111/j.1365-2036.1995.tb00360.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

1.  Chronic Functional Abdominal Pain (CFAP).

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-08

2.  Regional quantitation of preprodynorphin mRNA in guinea pig gastrointestinal tract.

Authors:  V P Yuferov; J A Culpepper-Morgan; K S LaForge; A Ho; M J Kreek
Journal:  Neurochem Res       Date:  1998-04       Impact factor: 3.996

Review 3.  Drug treatment options for irritable bowel syndrome: managing for success.

Authors:  R C Dunphy; G N Verne
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 4.  New developments in the treatment of functional dyspepsia.

Authors:  Vincenzo Stanghellini; Fabrizio De Ponti; Roberto De Giorgio; Giovanni Barbara; Cesare Tosetti; Roberto Corinaldesi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Activation of peripheral kappa opioid receptors inhibits capsaicin-induced thermal nociception in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

6.  Local administration of mu or kappa opioid agonists attenuates capsaicin-induced thermal hyperalgesia via peripheral opioid receptors in rats.

Authors:  M C Ko; J E Tuchman; M D Johnson; K Wiesenauer; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  2000-02       Impact factor: 4.530

Review 7.  New drugs in the management of the irritable bowel syndrome.

Authors:  M J Farthing
Journal:  Drugs       Date:  1998-07       Impact factor: 9.546

Review 8.  Pathophysiology and management of irritable bowel syndrome.

Authors:  J E Kellow
Journal:  Korean J Intern Med       Date:  2001-09       Impact factor: 2.884

Review 9.  Molecular Genetics of Kappa Opioids in Pain and Itch Sensations.

Authors:  Pang-Yen Tseng; Mark A Hoon
Journal:  Handb Exp Pharmacol       Date:  2022
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.